AR032891A1 - Compuesto derivado de hidroxiimino-fluoreno y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de proteinquinasa - Google Patents
Compuesto derivado de hidroxiimino-fluoreno y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de proteinquinasaInfo
- Publication number
- AR032891A1 AR032891A1 ARP010103906A ARP010103906A AR032891A1 AR 032891 A1 AR032891 A1 AR 032891A1 AR P010103906 A ARP010103906 A AR P010103906A AR P010103906 A ARP010103906 A AR P010103906A AR 032891 A1 AR032891 A1 AR 032891A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- manufacture
- substituted
- treatment
- fluorene
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 125000004001 thioalkyl group Chemical group 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- -1 Hydroxyimino-fluorene derivative compound Chemical class 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical group O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 201000003142 neovascular glaucoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003462 sulfoxides Chemical group 0.000 abstract 1
- 125000004962 sulfoxyl group Chemical group 0.000 abstract 1
- 125000005000 thioaryl group Chemical group 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuesto derivado de hidroxiimino-fluoreno de la formula (1) donde R5 y R6 son cada uno independientemente hidrogeno, halo, o un C1-8 alquilo, C1-8 alcoxi, arilo, heteroarilo, acilo, tioalquilo, sulfonilo, o sulfoxil sustituido o no sustituido; y X es C-Y o N, en donde Y es hidrogeno, halo, NH2, NO2, o un alquilo, cicloalquilo, heterocicloalquilo, alcoxi, alquenilo, arilo, heteroarilo, ariloxi, alquilamino, dialquilamino, tioalquilo, acilo, sulfonilo, sulfoxido o tioarilo, sustituido o no sustituido; o un profármaco farmacéuticamente aceptado de dicho compuesto, un metabolito farmacéuticamente activo de dicho compuesto, o una sal farmacéuticamente aceptada de dicho compuesto o metabolito. Estos compuestos y las composiciones farmacéuticas que los contienen, son capaces de mediar la transduccion de la senal de la tirosina quinasa para modular y/o inhibir la proliferacion de las células indeseables. También se describe el uso de dichos compuestos en la fabricacion de medicamentos para el tratamiento del cáncer y las otras enfermedades asociadas con la angiogénesis y/o proliferacion celular indeseable, tales como la retinopatía diabética, el glaucoma neovascular, la artritis reumatoides y la psoriasis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22480500P | 2000-08-18 | 2000-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032891A1 true AR032891A1 (es) | 2003-12-03 |
Family
ID=22842288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103906A AR032891A1 (es) | 2000-08-18 | 2001-08-15 | Compuesto derivado de hidroxiimino-fluoreno y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de proteinquinasa |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6462060B2 (es) |
| EP (1) | EP1309563B1 (es) |
| JP (1) | JP2004506720A (es) |
| AR (1) | AR032891A1 (es) |
| AT (1) | ATE295354T1 (es) |
| AU (1) | AU2001279090A1 (es) |
| BR (1) | BR0113258A (es) |
| CA (1) | CA2411924A1 (es) |
| DE (1) | DE60110802T2 (es) |
| ES (1) | ES2238463T3 (es) |
| GT (1) | GT200100170A (es) |
| MX (1) | MXPA03001452A (es) |
| PA (1) | PA8525701A1 (es) |
| PE (1) | PE20020289A1 (es) |
| SV (1) | SV2003000603A (es) |
| WO (1) | WO2002016326A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770652B2 (en) * | 2001-10-18 | 2004-08-03 | Duquesne University Of The Holy Ghost | Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
| WO2003061566A2 (en) * | 2002-01-24 | 2003-07-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anti-cancer combination and use thereof |
| JP4686465B2 (ja) * | 2003-10-16 | 2011-05-25 | イムクローン・リミテッド・ライアビリティ・カンパニー | 繊維芽細胞増殖因子レセプター−１阻害物質及びその治療方法 |
| CN101068561A (zh) * | 2004-10-06 | 2007-11-07 | 蒂尔坦制药有限公司 | 用于加强抗血管生成疗法的方法和组合物 |
| JP5117374B2 (ja) | 2005-03-29 | 2013-01-16 | イコス・コーポレイション | Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体 |
| WO2007026720A1 (ja) * | 2005-08-31 | 2007-03-08 | Taisho Pharmaceutical Co., Ltd. | 縮環ピラゾール誘導体 |
| CN119859229B (zh) * | 2025-03-21 | 2025-06-13 | 山东石油化工学院 | 一种用于从气体中脱除有机化合物的多孔材料的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5625031A (en) | 1994-02-08 | 1997-04-29 | Bristol-Myers Squibb Company | Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein |
| US5631156A (en) | 1994-06-21 | 1997-05-20 | The University Of Michigan | DNA encoding and 18 KD CDK6 inhibiting protein |
| US5916908A (en) | 1994-11-10 | 1999-06-29 | Cor Therapeutics, Inc. | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
| US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| US6514971B1 (en) | 1996-03-15 | 2003-02-04 | Zeneca Limited | Cinnoline derivatives and use as medicine |
| US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
| BR9709406B1 (pt) * | 1996-05-30 | 2009-05-05 | fluorenonas alquiloxiamino substituìdas e composição farmacêutica contendo as mesmas. | |
| GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
| ES2301194T3 (es) | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| CA2294244A1 (en) | 1997-07-12 | 1999-01-21 | Cancer Research Campaign Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| WO1999017769A1 (en) | 1997-10-06 | 1999-04-15 | Basf Aktiengesellschaft | INDENO[1,2-c]-, NAPHTHO[1,2-c]- AND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLE DERIVATIVES |
| RO119463B1 (ro) | 1997-10-27 | 2004-11-30 | Agouron Pharmaceuticals, Inc. | Derivaţi de 4-aminotiazol şi utilizarea lor ca inhibitori ai cdk |
| ZA9811178B (en) | 1997-12-13 | 2000-06-07 | Bristol Myers Squibb Co | Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors. |
| AU748178B2 (en) | 1998-02-26 | 2002-05-30 | Aventis Holdings Inc. | 6,9-disubstituted 2-(trans-(4- aminocyclohexyl) amino)purines |
| US6479487B1 (en) | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
| NZ507567A (en) | 1998-04-21 | 2003-08-29 | Du Pont Pharm Co | 5-aminoindeno(1,2-c)pyrazol-4-ones as anti-cancer and anti-proliferative agents |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| WO2000012485A1 (en) | 1998-08-29 | 2000-03-09 | Astrazeneca Ab | Pyrimidine compounds |
| ATE336484T1 (de) | 1998-08-29 | 2006-09-15 | Astrazeneca Ab | Pyrimidine verbindungen |
| WO2000014105A1 (en) * | 1998-09-08 | 2000-03-16 | Agouron Pharmaceuticals, Inc. | Modifications of the vegf receptor-2 protein and methods of use |
| CN1335836A (zh) * | 1998-11-06 | 2002-02-13 | 巴斯福股份公司 | 三环吡唑衍生物 |
-
2001
- 2001-07-31 DE DE60110802T patent/DE60110802T2/de not_active Expired - Fee Related
- 2001-07-31 CA CA002411924A patent/CA2411924A1/en not_active Abandoned
- 2001-07-31 JP JP2002521202A patent/JP2004506720A/ja not_active Withdrawn
- 2001-07-31 MX MXPA03001452A patent/MXPA03001452A/es active IP Right Grant
- 2001-07-31 ES ES01957334T patent/ES2238463T3/es not_active Expired - Lifetime
- 2001-07-31 WO PCT/US2001/023897 patent/WO2002016326A1/en not_active Ceased
- 2001-07-31 AT AT01957334T patent/ATE295354T1/de not_active IP Right Cessation
- 2001-07-31 BR BR0113258-0A patent/BR0113258A/pt not_active IP Right Cessation
- 2001-07-31 AU AU2001279090A patent/AU2001279090A1/en not_active Abandoned
- 2001-07-31 EP EP01957334A patent/EP1309563B1/en not_active Expired - Lifetime
- 2001-08-14 PE PE2001000808A patent/PE20020289A1/es not_active Application Discontinuation
- 2001-08-15 AR ARP010103906A patent/AR032891A1/es unknown
- 2001-08-16 US US09/930,255 patent/US6462060B2/en not_active Expired - Fee Related
- 2001-08-17 PA PA20018525701A patent/PA8525701A1/es unknown
- 2001-08-17 SV SV2001000603A patent/SV2003000603A/es unknown
- 2001-08-17 GT GT200100170A patent/GT200100170A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03001452A (es) | 2004-05-04 |
| US20020049238A1 (en) | 2002-04-25 |
| ES2238463T3 (es) | 2005-09-01 |
| EP1309563B1 (en) | 2005-05-11 |
| SV2003000603A (es) | 2003-01-13 |
| BR0113258A (pt) | 2003-07-15 |
| ATE295354T1 (de) | 2005-05-15 |
| CA2411924A1 (en) | 2002-02-28 |
| US6462060B2 (en) | 2002-10-08 |
| PE20020289A1 (es) | 2002-05-27 |
| EP1309563A1 (en) | 2003-05-14 |
| JP2004506720A (ja) | 2004-03-04 |
| DE60110802D1 (de) | 2005-06-16 |
| DE60110802T2 (de) | 2005-10-06 |
| AU2001279090A1 (en) | 2002-03-04 |
| PA8525701A1 (es) | 2002-04-25 |
| WO2002016326A1 (en) | 2002-02-28 |
| GT200100170A (es) | 2002-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032438A1 (es) | Compuesto derivado de indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento para tratar enfermedades proteinquinasa dependientes | |
| UY26190A1 (es) | Compuestos de tiazol y composiciones farmacéuticas para inhibir a las proteinquinasas y métodos para su utilización | |
| PA8592901A1 (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso | |
| ES2150113T3 (es) | Derivados de pirazol y procedimientos para la preparacion de los mismos. | |
| PA8550101A1 (es) | Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización | |
| UY28442A1 (es) | Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y métodos para intervenir en o inhibir la proliferacion celular | |
| SK17252002A3 (sk) | Deriváty acylfenylmočoviny, spôsoby ich výroby a použitie ako liečivo | |
| CY1107148T1 (el) | Παραγωγα ινδαζολης και φαρμακευτικες συνθεσεις για αναστολη των κινασων πρωτεϊνης και μεθοδοι για τη χρηση τους | |
| BR0110302A (pt) | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase | |
| IL289165B1 (en) | Substituted azole-dione compounds and pharmaceutical compositions comprising them | |
| AR053770A1 (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2. composiciones farmaceuticas. | |
| BR9910915A (pt) | Composto, processos para preparar um composto e para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
| KR890006540A (ko) | I-데속시노지리마이신 및 i- 데속시만노노지리마이신의 n-치환유도체, 이들의 제조방법 및 의약제로서의 용도 | |
| GT200400136A (es) | Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibirlaproliferacion celular. | |
| MY148937A (en) | Medicaments with hm74a receptor activity | |
| AR017852A1 (es) | COMPUESTOS DE PIRAZOLO (3,4-b)PIRIDINA Y SUS SALES, UTILES COMO INHIBIDORES DE LAS PROTEINA-QUINASAS DEPENDIENTES DE CICLINA, Y LAS COMPOSICIONESFARMACEUTICAS QUE LOS CONTIENEN, EVENTUALMENTE ASOCIADOS CON UN AGENTE ANTICANCER. | |
| UY25993A1 (es) | Procedimiento para preparar derivados del acido hidroxi-pipecolato hidroxamico | |
| AR032891A1 (es) | Compuesto derivado de hidroxiimino-fluoreno y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de proteinquinasa | |
| AR032763A1 (es) | Compuestos pirazol-tiazol, composicion farmaceutica que lo contiene, y el uso de dicho compuesto en la fabricacion de medicamentos para inhibir quinasas ciclino-dependientes | |
| TR199802331T2 (xx) | 2,4-Diaminopirimidin t�revleri. | |
| SE1550735A1 (en) | Ether analogues of galiellalactone | |
| WO2017100703A1 (en) | Ems analogues of lyn/src-tyrosine kinase inhibitors | |
| MX9405111A (es) | Nuevos derivados de (1-fenil-1-heterociclil)metanol y(1-fenil-1-heterociclil-metilamina). | |
| US11584760B2 (en) | Dithio ETP derivatives | |
| AU2023205038A1 (en) | Smarca2/4 inhibition as a strategy to treat tumors that harbor aberrant baf assemblies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |